Tags

Type your tag names separated by a space and hit enter

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
Mol Ther. 2005 Nov; 12(5):876-84.MT

Abstract

Glycogen storage disease type II (GSD-II; Pompe disease) is caused by a deficiency of acid alpha-glucosidase (GAA; acid maltase) and manifests as muscle weakness, hypertrophic cardiomyopathy, and respiratory failure. Adeno-associated virus vectors containing either a liver-specific promoter (LSP) (AAV-LSPhGAApA) or a hybrid CB promoter (AAV-CBhGAApA) to drive human GAA expression were pseudotyped as AAV8 and administered to immunocompetent GAA-knockout mice. Secreted hGAA was detectable in plasma between 1 day and 12 weeks postadministration with AAV-LSPhGAApA and only from 1 to 8 days postadministration for AAV-CBGAApA. No anti-GAA antibodies were detected in response to AAV-LSPhGAApA (<1:200), whereas AAV-CBhGAApA provoked an escalating antibody response starting 2 weeks postadministration. The LSP drove approximately 60-fold higher GAA expression than the CB promoter in the liver by 12 weeks following vector administration. Furthermore, the detected cellular immunity was provoked by AAV-CBhGAApA, as detected by ELISpot and CD4+/CD8+ lymphocyte immunodetection. GAA activity was increased to higher than normal and glycogen content was reduced to essentially normal levels in the heart and skeletal muscle following administration of AAV-LSPhGAApA. Therefore, liver-restricted GAA expression with an AAV vector evaded immunity and enhanced efficacy in GSD-II mice.

Links

  • Publisher Full Text

    • Authors+Show Affiliations

    Franco LM
    Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
    Sun B
    No affiliation info available
    Yang X
    No affiliation info available
    Bird A
    No affiliation info available
    Zhang H
    No affiliation info available
    Schneider A
    No affiliation info available
    Brown T
    No affiliation info available
    Young SP
    No affiliation info available
    Clay TM
    No affiliation info available
    Amalfitano A
    No affiliation info available
    Chen YT
    No affiliation info available
    Koeberl DD
    No affiliation info available

    MeSH

    AnimalsAntibody FormationCreatine KinaseCreatine Kinase, MM FormDNA, ViralDependovirusEnhancer Elements, GeneticGene Transfer TechniquesGenetic TherapyGenetic VectorsGlycogenGlycogen Storage Disease Type IIHumansLiverMiceMice, KnockoutMuscle, SkeletalPlasmidsPromoter Regions, Geneticalpha-Glucosidases

    Pub Type(s)

    Journal Article
    Research Support, N.I.H., Extramural
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    16005263

    Citation

    Franco, Luis M., et al. "Evasion of Immune Responses to Introduced Human Acid Alpha-glucosidase By Liver-restricted Expression in Glycogen Storage Disease Type II." Molecular Therapy : the Journal of the American Society of Gene Therapy, vol. 12, no. 5, 2005, pp. 876-84.
    Franco LM, Sun B, Yang X, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther. 2005;12(5):876-84.
    Franco, L. M., Sun, B., Yang, X., Bird, A., Zhang, H., Schneider, A., Brown, T., Young, S. P., Clay, T. M., Amalfitano, A., Chen, Y. T., & Koeberl, D. D. (2005). Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Molecular Therapy : the Journal of the American Society of Gene Therapy, 12(5), 876-84.
    Franco LM, et al. Evasion of Immune Responses to Introduced Human Acid Alpha-glucosidase By Liver-restricted Expression in Glycogen Storage Disease Type II. Mol Ther. 2005;12(5):876-84. PubMed PMID: 16005263.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. AU - Franco,Luis M, AU - Sun,Baodong, AU - Yang,Xiaoyi, AU - Bird,Andrew, AU - Zhang,Haoyue, AU - Schneider,Ayn, AU - Brown,Talmage, AU - Young,Sarah P, AU - Clay,Timothy M, AU - Amalfitano,Andrea, AU - Chen,Y T, AU - Koeberl,Dwight D, Y1 - 2005/07/06/ PY - 2004/10/01/received PY - 2005/04/28/revised PY - 2005/04/28/accepted PY - 2005/7/12/pubmed PY - 2006/1/7/medline PY - 2005/7/12/entrez SP - 876 EP - 84 JF - Molecular therapy : the journal of the American Society of Gene Therapy JO - Mol. Ther. VL - 12 IS - 5 N2 - Glycogen storage disease type II (GSD-II; Pompe disease) is caused by a deficiency of acid alpha-glucosidase (GAA; acid maltase) and manifests as muscle weakness, hypertrophic cardiomyopathy, and respiratory failure. Adeno-associated virus vectors containing either a liver-specific promoter (LSP) (AAV-LSPhGAApA) or a hybrid CB promoter (AAV-CBhGAApA) to drive human GAA expression were pseudotyped as AAV8 and administered to immunocompetent GAA-knockout mice. Secreted hGAA was detectable in plasma between 1 day and 12 weeks postadministration with AAV-LSPhGAApA and only from 1 to 8 days postadministration for AAV-CBGAApA. No anti-GAA antibodies were detected in response to AAV-LSPhGAApA (<1:200), whereas AAV-CBhGAApA provoked an escalating antibody response starting 2 weeks postadministration. The LSP drove approximately 60-fold higher GAA expression than the CB promoter in the liver by 12 weeks following vector administration. Furthermore, the detected cellular immunity was provoked by AAV-CBhGAApA, as detected by ELISpot and CD4+/CD8+ lymphocyte immunodetection. GAA activity was increased to higher than normal and glycogen content was reduced to essentially normal levels in the heart and skeletal muscle following administration of AAV-LSPhGAApA. Therefore, liver-restricted GAA expression with an AAV vector evaded immunity and enhanced efficacy in GSD-II mice. SN - 1525-0016 UR - https://www.unboundmedicine.com/medline/citation/16005263/Evasion_of_immune_responses_to_introduced_human_acid_alpha_glucosidase_by_liver_restricted_expression_in_glycogen_storage_disease_type_II_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1525-0016(05)00231-5 DB - PRIME DP - Unbound Medicine ER -